Status:
TERMINATED
Organoid Model Predictive of Response to Immunotherapies
Lead Sponsor:
Indiana University
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to create models out of tissue samples and treat those models with the same immunotherapy treatment the patient will be receiving, in order to validate this process and to...
Eligibility Criteria
Inclusion
- ≥ 18 years old at the time of informed consent
- Ability to provide written informed consent and HIPAA authorization
- Biopsy proven diagnosis of cancer
- Able to obtain at least 2 16 gage cores of fresh tissue safely (3 or more cores preferred)
- Planning to undergo standard of care Immunotherapy
- Baseline standard of care CT within 8 weeks of starting Immunotherapy
Exclusion
- Inability to provide fresh biopsy sample
- Any active infections
- Any conditions that in the opinion of treating physician and the study team will compromise the ability of the patient to receive prescribed treatment to assess the response.
Key Trial Info
Start Date :
January 22 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 26 2024
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT06084676
Start Date
January 22 2024
End Date
February 26 2024
Last Update
July 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States, 46202